AI Article Synopsis
- Osteosarcoma (OS) is difficult to treat due to its aggressive nature and the resistance to current therapies, leading to low survival rates.
- Accurate preclinical models, such as cell lines and animal models, are crucial for developing and validating new treatments for OS.
- The review discusses the advancements in drug discovery for OS, highlighting successful therapeutic options and emphasizing the potential for personalized treatments.
Article Abstract
The management of osteosarcoma (OS) patients presents a significant clinical challenge. Despite progress in conventional and targeted therapies, the survival rate of OS patients remains limited largely due to therapy resistance and the high metastatic potential of the disease. OS models that accurately reflect the fundamental characteristics are vital to the innovation and validation of effective therapies. This review provides an insight into the advances and challenges in OS drug development, focusing on various preclinical models, including cell lines, 3D culture models, murine models, and canine models. The relevance, strengths, and limitations of each model in OS research are explored. In particular, we highlight a range of potential therapeutics identified through these models. These instances of successful drug development represent promising pathways for personalized OS treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527053 | PMC |
| http://dx.doi.org/10.3390/biom13091362 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!